Canis ISSN: 2398-2942

Trilostane

Synonym(s): WIN 24, 540, Modrenal, Vetoryl

Contributor(s): Francesca Gordon, Ian Ramsey

Introduction

Name

  • Trilostane.

Class of drug

  • Adrenocortical suppressant (inhibits the 3-beta-hydroxysteroid dehydrogenase isomerase enzyme system).

Description

Chemical name

  • (4-alpha, 5-alpha, 17-beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile.

Molecular formula

  • C20H27NO3.

Molecular weight

  • 329.44.

Physical properties

  • White or almost white crystalline powder.

Storage requirements

  • Store in a dry place.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Do not use with other drugs suppressing adrenal function, eg mitotane Mitotane. The risk of hyperkalemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or ACE inhibitors ACE inhibitor: overview. The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from VetMed Resource and PubMed.
  • Ramsey I & Ristic J (2007) The diagnosis of canine hyperadrenocorticism. In Practice 29, 226-454.
  • Ramsey I & Neiger R (2007) The treatment of canine hyperadrenocorticism. In Practice 29, 512-519.
  • Bell R, Neiger R, McGrotty Y & Ramsey I K (2006) Study of the effects of once daily trilostane administration on cortisol concentrations and ACTH responsiveness in hyperadrenocorticoid dogs. Vet Rec 159,277-281 PubMed.
  • Ramsey I (2006) Diagnosis of canine hyperadrenocorticism. UK Vet 11(1), 21-28.
  • Ramsey I (2005) Pathophysiology of hyperadrenocorticism. UK Vet 10(8), 31-37.
  • Barker E, Campbell S, Tebb A, Neiger R, Herrtage M E, & Ramsey I K (2005) A comparison of the survival times of dogs treated for hyperadrenocorticism with trilostane or mitotane.JVIM19, 810-815 PubMed.
  • Chapman P S, Kelly D F, Archer J, Brockman D J, Neiger R (2004) Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. JSAP 45, 307-310 PubMed.
  • Wenger M, Sieber-Ruckstuhl NS, Muller C and Reusch CE (2004) Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 65, 1245-1250 PubMed.
  • Neiger R (2003) Treatment of canine hyperadrenocorticism (Cushing's Disease) with trilostane. UK Vet 8(2) 19-22.
  • Ruckstuhl N S, Nett C S & Reusch C E (2002) Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 63, 506512.
  • Neiger R, Ramsey I, O'Connor J, Hurley K J & Mooney C T (2002) Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism.Vet Rec150,799-804PubMed.
  • Neiger R & Hurley K (2000) Long-term efficacy and safety of trilostane for treatment of canine hyperadrenocorticism.JVIM14, 376.

Other sources of information

  • www.canine-cushings.co.uk
  • Vetoryl® Capsules: www.dechra-us.com/products/details/vetoryl%C2%AE-capsules-(trilostane)-5-mg
  • Eastwood J M, Elwood C M (2003) Prolonged hypoadrenocorticism in five dogs treated with trilostane for pituitary dependent hyperadrenocorticism(abstract). Proceedings of the British Small Animal Veterinary Association, BSAVA Publications, Gloucester, 587.
  • Eastwood J M, Elwood C M & Hurley K J (2001)Trilostane treatment of four dogs with functional adrenocortical neoplasia.ESVIM Congress, Dublin.
  • Neiger R & Hurley K (2001) 24 hour cortisol values in dogs with hyperadrenocorticism on trilostaneBSAVA Congress, Birmingham.
  • Ramsey I & McGrotty Y (2001) The effect of trilostane on ACTH stimulation tests performed at two different times post-treatmentESVIM Congress, Dublin.
  • Hurley K (1998) Trilostane in the treatment of canine hyperadrenocorticismESVIM Congress, Vienna, Austria.

ADDED